Yuanquan Yang
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Yuanquan Yang sits in the upper half of US sponsors by registered trial count (#4,885 of 15,742 sponsors by registered trial count).
Yuanquan Yang: 2 sponsored US clinical trials, 2 recruiting.
Yuanquan Yang sponsors 2 registered US clinical trials on ClinicalTrials.gov, 2 of them currently recruiting. 0 of these trials are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Stage IIIA Bladder Cancer AJCC v8, with 1 trials.
Mid-pack sponsor footprint
Yuanquan Yang is in the upper half of sponsors by trial count (#4,885 of 15,742 sponsors by registered trial count). Use the pipeline list and therapeutic areas to see what drives that mid-pack volume.
Open and recent trials
2 total, page 1 of 1
Futibatinib in Combination With Durvalumab Prior to Cystectomy for the Treatment of Muscle-Invasive Bladder Cancer Patients Who Are Ineligible for Cisplatin-based Therapy
NCT06263153
Siltuximab for the Prevention of Severe Immune-Related Adverse Events During Immune Checkpoint Inhibitor Rechallenge in Patients With Advanced Cancer, CIRES Trial
NCT06470971
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 2 |
What is open in the Yuanquan Yang pipeline
2 recruiting of 2 indexed (100% open).
Phase mix: 0 late (III/IV) vs 2 early (I/II) (early-phase heavy).
Top condition: Stage IIIA Bladder Cancer AJCC v8 (1 trial), 5 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Yuanquan Yang: open-pipeline peers nationwide
Peers matched on 2 registered trials and 100% open enrollment, not the therapeutic-area sidebar.
Yuanquan Yang sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 2 trials (± recruiting share)
- 1200 Pharma · 2 trials · 50% recruiting
- 1ST Biotherapeutics · 2 trials · 50% recruiting
- 3 Waves Wellness · 2 trials · 0% recruiting
- 3EO Health · 2 trials · 0% recruiting
Sponsors near 100% open enrollment (± trial volume)
- AAVantgarde Bio Srl · 100% recruiting · 2 trials
- Acorn Biolabs · 100% recruiting · 3 trials
- Acrivon Therapeutics · 100% recruiting · 2 trials
- ADARx Pharmaceuticals · 100% recruiting · 4 trials
Related
What to do with this Yuanquan Yang page
2 registered trials is a research-attention snapshot, not an endorsement of Yuanquan Yang or any single study.
- 2 of Yuanquan Yang's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Stage IIIA Bladder Cancer AJCC v8 is the condition Yuanquan Yang studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Stage IIIA Bladder Cancer AJCC v8 trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Yuanquan Yang pipeline card: 2 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.